top of page

Latest Articles and Analysis

Search

At a MAHA Institute event on Monday, Health Secretary Robert F. Kennedy Jr. announced plans to help people wean off antidepressants. Kennedy is pictured here arriving at another Make America Healthy Again event in November 2025.

At a MAHA Institute event on Monday, Health Secretary Robert F. Kennedy Jr. announced plans to help people wean off antidepressants. Kennedy is pictured here arriving at another Make America Healthy Again event in November 2025.

When the Target Is SSRIs, the Risk Is the Six Protected Classes

On May 4, 2026, Health Secretary Robert F. Kennedy Jr. closed a daylong Make America Healthy Again (MAHA) Institute summit on mental health and overmedicalization by announcing a federal initiative...

Health Equity & Community Care

May 186 min read

A close-up of an open hand holding multiple HIV medication pills of different shapes, sizes, and colors.

A close-up of an open hand holding multiple HIV medication pills of different shapes, sizes, and colors.

A New Single-Tablet Option for HIV's "Forgotten Population" Could Change Lives. Will Policy Let It?

New Phase 3 data show a single-tablet regimen of bictegravir/lenacapavir could finally bring one-pill simplicity to long-term HIV survivors locked into complex regimens by decades of drug resistance. The science is closing the treatment gap. Will our policy systems do the same?

HIV/AIDS Policy

Mar 309 min read

President Trump speaks at a podium in the Roosevelt Room of the White House, surrounded by four senior health officials in suits. To the right, a large poster titled "Biden's Bad Drug Price Deal" displays a bar chart comparing U.S. prescription drug prices to those in other countries, showing significantly higher costs for Americans.

President Trump speaks at a podium in the Roosevelt Room of the White House, surrounded by four senior health officials in suits. To the right, a large poster titled "Biden's Bad Drug Price Deal" displays a bar chart comparing U.S. prescription drug prices to those in other countries, showing significantly higher costs for Americans.

Third Wave of Medicare Drug Price Negotiation Adds More Potential Peril

Medicare drug negotiation's third wave includes Biktarvy, raising HIV treatment access concerns.

Healthcare Access & Affordability

Feb 155 min read

CMS Draft Guidance Creates Regulatory Vacuum in 340B Drug Pricing

CMS Draft Guidance Creates Regulatory Vacuum in 340B Drug Pricing

CMS Draft Guidance Creates Regulatory Vacuum in 340B Drug Pricing

CMS draft guidance on 340B claims modifiers creates ambiguity and enforcement gaps threatening program integrity and beneficiary access.

Healthcare Access & Affordability

Jun 1, 20257 min read

Blame Payers for Only 1:3 Patients Receiving HCV Cure

Only 35% of privately insured and 23% of Medicaid patients initiate HCV treatment due to payer barriers.

Health Equity & Community Care

Aug 14, 20223 min read

Institutional Barriers Still Stand in the Way to Equity

Innovative HIV medications available but inaccessible: payer barriers block Cabenuva and Apretude access.

Health Equity & Community Care

Jul 31, 20223 min read

2022: New Beginnings, New Changes

CANN announces 2022 organizational changes including rebranding and launching the 340B Action Center.

Health Equity & Community Care

Community Access National Network

Jan 2, 20223 min read

Biden Administration's Healthcare Future is One of Promise & Peril

Analyzes Biden health policy priorities including drug pricing reform and Medicare expansion.

Healthcare Access & Affordability

Sep 12, 20216 min read

We Need Your Support Today!

bottom of page